Kamioka Norihiko, Soga Yoshimitsu, Kuramitsu Shoichi, Iida Osamu, Hirano Keisuke, Suzuki Kenji, Kawasaki Daizo, Yamaoka Terutoshi, Suematsu Nobuhiro, Shintani Yoshiaki, Miyashita Yusuke, Takahashi Hiroki, Tsuchiya Taketsugu, Shinozaki Norihiko, Okazaki Shinya, Ando Kenji
Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
Kansai Rosai Hospital, Cardiovascular Center, Amagasaki, Japan.
Catheter Cardiovasc Interv. 2017 Nov 1;90(5):790-797. doi: 10.1002/ccd.27192. Epub 2017 Jul 19.
We sought to assess whether balloon angioplasty (BA) alone for small femoropopliteal disease improved the outcome following endovascular therapy as compared with stent implantation.
The optimal strategy of endovascular therapy for small vessel arteries in femoropopliteal disease remains unclear.
We performed a multicenter retrospective analysis of 337 consecutive patients (371 limbs) with femoropopliteal arteries 4.0 mm or less in diameter and 150 mm or less in length.
Cumulative 3-year incidence of primary patency was significantly higher in the BA group than in the stent group (53.8% vs. 34.2%, P = 0.002). While assisted-primary patency and freedom from any major adverse limb events were also significantly higher in the BA group than in the stent group (70.9% vs. 44.2%, P < 0.001 and 60.6% vs. 36.4%, P = 0.001, respectively), secondary patency did not significantly differ between the two groups (86.9% vs. 86.9%, P = 0.67). Predictors of restenosis were diabetes mellitus (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.14-2.31; P = 0.01), no administration of cilostazol (HR, 1.50; 95% CI, 1.07-2.13; P = 0.02), stent implantation (HR, 1.68; 95% CI, 1.15-2.41; P = 0.01), and lesion length >75.0 mm(HR, 2.09; 95% CI, 1.50-2.92; P < 0.001).
Lesions in small (<4.0 mm diameter) FP vessels demonstrated better primary patency at 3 years when successfully treated with balloon angioplasty alone as opposed to routine or bailout stenting. This difference was especially pronounced for lesions 75 to 150 mm in length.
我们试图评估对于小的股腘动脉疾病,单纯球囊血管成形术(BA)与支架植入相比,在血管内治疗后是否能改善预后。
股腘动脉疾病中小血管动脉的最佳血管内治疗策略仍不明确。
我们对337例连续患者(371条肢体)进行了多中心回顾性分析,这些患者的股腘动脉直径为4.0mm或更小,长度为150mm或更小。
BA组的3年累计原发性通畅率显著高于支架组(53.8%对34.2%,P = 0.002)。虽然BA组的辅助原发性通畅率和无任何主要肢体不良事件发生率也显著高于支架组(分别为70.9%对44.2%,P < 0.001和60.6%对36.4%,P = 0.001),但两组的继发性通畅率无显著差异(86.9%对86.9%,P = 0.67)。再狭窄的预测因素包括糖尿病(风险比[HR],1.61;95%置信区间[CI],1.14 - 2.31;P = 0.01)、未使用西洛他唑(HR,1.50;95% CI,1.07 - 2.13;P = 0.02)、支架植入(HR,1.68;95% CI,1.15 - 2.41;P = 0.01)以及病变长度>75.0mm(HR,2.09;95% CI,1.50 - 2.92;P < 0.001)。
直径小于4.0mm的股腘血管病变,单独采用球囊血管成形术成功治疗时,3年时的原发性通畅情况优于常规或补救性支架植入。这种差异在长度为75至150mm的病变中尤为明显。